Want to see HK:0853 full AI Analyst Report?
Top Page
MicroPort Scientific
(0853)
Select Model
Select Model
Rating:45Neutral
Price Target:
HK$6.00
â–¼(-4.46% Downside)
Action:Reiterated
Date:07/04/26
Overall score reflects an improving but still fragile financial profile, led by weak cash generation (negative free cash flow) and elevated leverage despite the return to positive net income. Technicals add pressure with a clear downtrend across key moving averages and negative MACD. Valuation (P/E ~32) does not sufficiently offset these risks given the ongoing operational and cash-flow challenges.
Positive Factors
Diversified medical-device portfolio
Exposure across cardiovascular, orthopedic, and specialty devices gives MicroPort multiple avenues for procedure-driven growth. Geographic reach across China and international markets can diversify demand and reduce dependence on any single therapeutic area or healthcare system over the medium term.
Negative Factors
Declining revenue
Revenue contraction suggests that product demand, pricing, or commercialization momentum has not yet established a durable growth trajectory. For a device company, weaker sales can limit operating leverage, reduce reinvestment capacity, and make the recent profitability improvement harder to sustain.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified medical-device portfolio
Exposure across cardiovascular, orthopedic, and specialty devices gives MicroPort multiple avenues for procedure-driven growth. Geographic reach across China and international markets can diversify demand and reduce dependence on any single therapeutic area or healthcare system over the medium term.
Read all positive factors
MicroPort Scientific (0853) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$11.65B
Dividend Yield0.06%
Average Volume (3M)9.32M
Price to Earnings (P/E)31.2
Beta (1Y)1.68
Revenue Growth-3.62%
EPS GrowthN/A
CountryHK
Employees6,547
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.02
Shares Outstanding1,917,386,600
10 Day Avg. Volume5,999,952
30 Day Avg. Volume9,315,507
Financial Highlights & Ratios
PEG Ratio-0.45
Price to Book (P/B)2.65
Price to Sales (P/S)2.61
P/FCF Ratio-33.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.05
Revenue Forecast (FY)HK$1.19B
MicroPort Scientific Business Overview & Revenue Model
Company Description
MicroPort Scientific Corp. is an investment holding company, which engages in the research and development, manufacture, and distribution of medical devices. It operates through the following segments: Cardiovascular Devices Business, Orthopedics ...
How the Company Makes Money
MicroPort primarily makes money by selling medical devices and related products to hospitals and healthcare providers, earning revenue when its products are implanted or used in clinical procedures. Key revenue streams generally include: (1) Produ...
MicroPort Scientific Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
52
Neutral
Cash Flow
32
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 996.38M | 1.03B | 950.73M | 840.83M | 778.64M |
| Gross Profit | 554.33M | 574.09M | 532.10M | 501.77M | 491.77M |
| EBITDA | 88.83M | -45.30M | -382.54M | -430.26M | -256.35M |
| Net Income | 48.59M | -214.04M | -477.63M | -436.51M | -276.48M |
Balance Sheet | |||||
| Total Assets | 3.70B | 3.63B | 3.93B | 3.99B | 4.38B |
| Cash, Cash Equivalents and Short-Term Investments | 813.82M | 974.48M | 1.06B | 1.24B | 1.75B |
| Total Debt | 1.60B | 1.69B | 1.70B | 1.47B | 1.24B |
| Total Liabilities | 2.20B | 2.49B | 2.53B | 2.20B | 2.16B |
| Stockholders Equity | 980.69M | 603.47M | 757.82M | 1.14B | 1.49B |
Cash Flow | |||||
| Free Cash Flow | -77.73M | -158.10M | -430.99M | -600.58M | -505.45M |
| Operating Cash Flow | 9.21M | -49.67M | -231.87M | -343.30M | -257.53M |
| Investing Cash Flow | 98.29M | -149.73M | -376.81M | -412.75M | -655.74M |
| Financing Cash Flow | -151.39M | -97.92M | 434.90M | 273.00M | 1.66B |
MicroPort Scientific Technical Analysis
Negative
6.28
Price Trends
6.62
Negative
7.26
Negative
9.03
Negative
Market Momentum
-0.19
Positive
36.91
Neutral
27.47
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0853, the sentiment is Negative. The current price of 6.28 is below the 20-day moving average (MA) of 6.48, below the 50-day MA of 6.62, and below the 200-day MA of 9.03, indicating a bearish trend. The MACD of -0.19 indicates Positive momentum. The RSI at 36.91 is Neutral, neither overbought nor oversold. The STOCH value of 27.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0853.
MicroPort Scientific Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | HK$1.75B | 17.75 | 8.26% | ― | 59.30% | 131.03% | |
63 Neutral | HK$1.96B | 14.05 | 8.16% | ― | 20.65% | 127.07% | |
59 Neutral | HK$5.98B | 92.65 | 1.72% | ― | 0.75% | -20.22% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$3.43B | -20.55 | -7.65% | ― | 21.23% | 36.89% | |
45 Neutral | HK$11.65B | 31.24 | 6.07% | 0.06% | -3.62% | ― | |
34 Underperform | HK$125.80M | -1.28 | -22.16% | 2.02% | -28.07% | 47.54% |
* Healthcare Sector Average
HK:0853
MicroPort Scientific
6.08
-7.83
-56.29%
HK:9996
Peijia Medical Ltd.
5.06
-2.65
-34.37%
HK:6669
Acotec Scientific Holdings Limited
6.01
-8.62
-58.92%
HK:1302
LifeTech Scientific Corporation
1.38
-0.56
-28.87%
HK:2393
Yestar Healthcare Holdings Co Ltd
0.06
-0.07
-56.92%
HK:6609
Shanghai Heartcare Medical Technology Corp. Ltd. Class H
48.20
-14.80
-23.49%
MicroPort Scientific Corporate Events
MicroPort Delays 2026 Interim Results, Trading Suspended Amid Lease Review
Aug 31, 2026
MicroPort Scientific Corporation, a Hong Kong-listed medical device maker incorporated in the Cayman Islands, develops and markets cardiovascular and other minimally invasive products to hospital and clinical customers worldwide. Its equity and de...
MicroPort Revamps Board With New Non-Executive Director and Committee Chair
Aug 28, 2026
MicroPort Scientific Corporation has announced board and committee changes effective 28 August 2026, with non-executive director Dr. Qingbing Men stepping down from the board, the audit committee and the chairmanship of the strategic committee to ...
MicroPort Scientific Clarifies Board and Committee Composition
Aug 28, 2026
MicroPort Scientific Corporation has announced the current composition of its board of directors, listing one executive director serving as chairman, several non-executive directors, and four independent non-executive directors. This disclosure cl...
MicroPort’s Endovastec Unit Delivers First-Half Revenue and Profit Growth
Aug 26, 2026
MicroPort’s associate Shanghai MicroPort Endovascular MedTech (Endovastec) reported unaudited revenue of RMB 793.9 million for the six months to 30 June 2026, up 11.1% year-on-year, with profit rising 2.7% to RMB 376.8 million and net profit...
MicroPort updates Shanghai facility lease renewals amid ongoing negotiations
Aug 20, 2026
MicroPort Scientific has updated investors on the renewal of leases for its key industrial property in Shanghai’s Pilot Free Trade Zone. Three subsidiaries have signed new agreements with BlueOrange Capital for 13,872.64 sq.m of space, exten...
MicroPort Scientific Sets Board Meeting to Approve Interim 2026 Results
Aug 19, 2026
MicroPort Scientific has scheduled a board meeting for August 31, 2026 to review and approve its interim results for the six months ended June 30, 2026, and to address other corporate business. The timing signals an upcoming disclosure of the comp...
MicroPort Scientific Signals Operating Turnaround Amid Persistent Net Loss
Aug 12, 2026
MicroPort Scientific has reported strong preliminary revenue growth for the six months ended June 30, 2026, with continuing operations up about 12% to 14% and overseas sales surging roughly 140%, excluding foreign exchange effects. Operating profi...
MicroPort to Sell Majority Stake in Orthopedics Unit to Tinavi
Jul 29, 2026
MicroPort Scientific, a Cayman Islands–incorporated medical device maker listed in Hong Kong, operates through subsidiaries including Suzhou MicroPort and Shanghai MicroPort Orthopedics, focusing on orthopedic products and broader healthcare...
MicroPort Weighs Strategic Sale of Overseas Orthopedics Unit to Tinavi
Jul 15, 2026
MicroPort Scientific’s orthopedics arm, Shanghai MicroPort Orthopedics, is the Group’s core international platform for hip and knee reconstruction, supplying innovative, clinically validated joint prostheses to major overseas markets. ...
MicroPort Wins Shareholder Backing for Board Changes and Capital Mandates
Jun 30, 2026
MicroPort Scientific Corporation reported that all resolutions at its 30 June 2026 annual general meeting were approved by shareholders via poll, including receipt of the 2025 financial statements, re-election of several non-executive and independ...
MicroPort Scientific Sets Out Board Structure and Key Committee Roles
Jun 30, 2026
MicroPort Scientific Corporation has announced the current composition of its board of directors, naming Dr. Zhaohua Chang as chairman and detailing the mix of executive, non-executive and independent non-executive directors. The company also conf...
MicroPort sets 2026 AGM to seek director renewals and fresh capital mandates
Jun 8, 2026
MicroPort Scientific has convened its next annual general meeting for 30 June 2026 in Shanghai, where shareholders will review the audited financial statements for the year ended 31 December 2025 and receive reports from the board and external aud...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.